| Old Articles: <Older 8031-8040 Newer> |
|---|
 |
The Motley Fool
November 3, 2011
David Williamson |
Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100.   |
The Motley Fool
November 3, 2011
Brian Orelli |
Modest Growth, Less-Than-Modest Stock Drop Dendreon's investors aren't happy. |
Chemistry World
November 3, 2011
Andrew Turley |
Taming Osmosis for Steady Drug Delivery Inspired by how plants transport fluids, a German start up has developed a pump that uses osmosis to deliver a liquid drug without electrical power or mechanical parts. |
The Motley Fool
November 3, 2011
Frank Vinluan |
GSK Settles With Uncle Sam for $3B GSK said the settlement will reduce financial uncertainty for the company and is in the best interest of shareholders. |
The Motley Fool
November 3, 2011
Brian Orelli |
FDA Approves! Investors Shrug. Investors just aren't that into MELA Sciences' newly approved melanoma detection device. |
The Motley Fool
November 3, 2011
Sean Williams |
Bash My Stock: Ariad Pharmaceuticals For those of you who've wondered what's wrong with your stock... |
The Motley Fool
November 3, 2011
Keki Fatakia |
Should You Be Worried About Danaher? Danaher reports 46% higher revenues, but why are profits down? |
The Motley Fool
November 3, 2011
Dan Caplinger |
Has Baxter International Become the Perfect Stock? Baxter needs to keep working on getting its debt levels down and seek out new growth opportunities. With favorable demographic winds at its back, Baxter could be the rare stock to actually reach perfection. |
The Motley Fool
November 2, 2011
David Williamson |
After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock. |
The Motley Fool
November 2, 2011
Brian Orelli |
Lipitor Loss Looming, Pfizer Shines Good thing it's already priced in. |
| <Older 8031-8040 Newer> Return to current articles. |
